Kala Pharmaceuticals (KALA) Revenue & Revenue Breakdown
Kala Pharmaceuticals Revenue Highlights
00
Kala Pharmaceuticals Revenue by Period
Kala Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $3.89M | -65.37% |
| 2021-12-31 | $11.24M | 76.67% |
| 2020-12-31 | $6.36M | 4.74% |
| 2019-12-31 | $6.07M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | -100.00% |
| 2015-12-31 | $45.00K | - |
Kala Pharmaceuticals generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Kala Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $70.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $1.23M | 192.38% |
| 2022-09-30 | $420.00K | -80.00% |
| 2022-06-30 | $2.10M | 53.06% |
| 2022-03-31 | $1.37M | -26.08% |
| 2021-12-31 | $1.86M | -39.48% |
| 2021-09-30 | $3.07M | 0.52% |
| 2021-06-30 | $3.05M | -6.58% |
| 2021-03-31 | $3.27M | 45.93% |
| 2020-12-31 | $2.24M | 0.81% |
| 2020-09-30 | $2.22M | 166.51% |
| 2020-06-30 | $833.00K | -22.22% |
| 2020-03-31 | $1.07M | -9.24% |
| 2019-12-31 | $1.18M | -18.68% |
| 2019-09-30 | $1.45M | -29.46% |
| 2019-06-30 | $2.06M | 48.41% |
| 2019-03-31 | $1.39M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Kala Pharmaceuticals generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Kala Pharmaceuticals Revenue Breakdown
Kala Pharmaceuticals Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|
| Sales discounts and contractual fee for service arrangements | $20.00K | $2.06M | $1.54M |
Latest
Kala Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: Sales discounts and contractual fee for service arrangements (100.00%).
Kala Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|
| Sales discounts and contractual fee for service arrangements | $20.00K | $2.06M | $1.54M |
Latest
Kala Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 22: Sales discounts and contractual fee for service arrangements (100.00%).
Kala Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| ORGO | Organogenesis | $433.14M | $115.18M |
| DVAX | Dynavax | $232.28M | $79.34M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| DERM | Journey Medical | $79.18M | $14.86M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| AKAN | Akanda | $2.16M | $762.61K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| KALA | Kala Pharmaceuticals | - | - |